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The first case was a 27-year-old female nonsmoker who was diagnosed with advanced adenocarcinoma with bone 
and brain metastases. A FISH study of a biopsy sample of the 
left clavicle detected ALK rearrangement, and the patient was 
confirmed to harbor variant 2 of the EML4-ALK fusion gene 
by reverse transcription-polymerase chain reaction (RT-PCR) 
and direct sequencing (Figure 1A). After the failure of first-line 
chemotherapy with cisplatin plus pemetrexed (Figure 1B), the 
patient was enrolled in a phase III study comparing crizotinib 
with standard chemotherapy in patients with ALK-rearranged 
non-small-cell lung cancer (NSCLC), and was then randomized 
to crizotinib. Although the patient experienced a partial response 
(Figure 1C), a relapse of brain metastases was observed approxi-
mately 8 months after the administration of crizotinib, and ste-
reotactic radiotherapy was administered. The patient continued 
to be treated with crizotinib beyond the progression of the brain 
metastases, and pleural effusion became evident 1 year and 
6 months after the first administration of crizotinib, and gradu-
ally expanded (Figure 1D). A rebiopsy of the pleural effusion 
showed a previously unidentified secondary mutation of the 
ALK gene at codon 1171 (I1171T; Figure 1E).
The second case was a 49-year-old female nonsmoker 
with locally advanced NSCLC, which was first treated with 
chemoradiation using cisplatin plus vinorelbine (radiation 
dose: 60 Gy in total). Approximately 7 months after the start 
of chemoradiation, positron emission tomography/computed 
tomography (PET/CT) showed multiple skin, hepatic and 
bone metastases, and variant 3 of the EML4-ALK fusion 
was identified by fluorescence in situ hybridization (FISH), 
immunohistochemistry (IHC), and RT-PCR of a biopsied skin 
lesion (Figure 2A). Second-line chemotherapy with peme-
trexed led to a partial response, but the patient experienced 
disease failure after eight cycles (Figure 2B). Thereafter, the 
patient was enrolled in a phase I study investigating alectinib, 
and the agent induced tumor reduction in the primary lesion 
and hepatic metastases, as shown in Figure 2C. However, a 
relapse of the primary lesion and hepatic metastases was seen 
approximately 7 months after the administration of alectinib 
(Figure 2D), and a rebiopsy of the hepatic lesion showed a 
secondary mutation of the ALK gene at codon 1171 (I1171N; 
Figure 2E). In both cases, bypass track resistance through the 
activation of an alternative driver oncogene, such as EGFR or 
KRAS, was not identified.
Various mechanisms which confer resistance to crizo-
tinib have been identified, including secondary mutations, 
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FIGURE 1.  Direct sequencing by capillary electrophoresis 
of a biopsy sample obtained from the left clavicle before 
crizotinib treatment using an ABI PRISM 310 Genetic 
Analyzer (A). Computed tomography scans showed meta-
static mediastinal lymph nodes before (B) and approxi-
mately 7 months after the administration of crizotinib (C). 
There was expansion of the pleural effusion with no relapse 
of the mediastinal lymph nodes (D). Direct sequencing of a 
biopsy sample of pleural effusion after a relapse on crizo-
tinib identified a secondary mutation of the ALK gene at 
codon 1171 (I1171T) (E).
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a copy number gain of the ALK gene, the activation of 
other oncogenes and so on.1 With regard to the secondary 
mutations of the ALK gene, different mutations have been 
observed to confer resistance to crizotinib and second-gen-
eration ALK inhibitors, such as ceritinib and alectinib (i.e., 
those conferring resistance to crizotinib include 1152Tins, 
L1152R, C1156Y, F1174C/L, L1196M, G1202R, D1203N, 
S1206Y, and G1269A; G1202R and F1174C/V confer resis-
tance to ceritinib; G1202R confers resistance to alectinib, 
whereas mutations at codon 1174 do not confer resistance to 
alectinib).1–6 Although an in vitro mutagenesis screen iden-
tified I1171T in the ALK gene, mutations at codon 1171, 
which is located in the vicinity of the kinase DFG (Asp-Phe-
Gly) motif of the activation loop, have yet to be identified 
in patients with ALK-rearranged NSCLC who have acquired 
resistance to ALK inhibitors.7 In addition, in vitro analyses 
by Friboulet et al2 and Ceccon et al8 showed that I1171T 
and I1171N confer resistance to crizotinib. In addition to 
the novel finding of mutations at I1171 in ALK-rearranged 
patients, it is intriguing that mutations at I1171 confer resis-
tance to both crizotinib and alectinib, which is a represen-
tative second-generation ALK inhibitor. It remains unclear 
why these mutations confer resistance to both of these 
agents; however, further basic and clinical analyses are war-
ranted to investigate the biological and clinical significance 
of mutations at I1171.
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FIGURE 2.  Direct sequencing by capil-
lary electrophoresis of a biopsy sample 
obtained from the skin metastasis before 
the administration of alectinib using an 
ABI PRISM 310 Genetic Analyzer (A). 
Computed tomography scans showing 
the primary lesion in the right lower lobe 
and hepatic metastases before (B) and 
approximately 4 months after (C) the 
administration of alectinib. A computed 
tomography scan indicating the relapse 
of the primary lesion and hepatic metas-
tases approximately 7 months after the 
administration of alectinib (D). Direct 
sequencing of a biopsy sample obtained 
from the hepatic metastasis after a 
relapse on alectinib showing a secondary 
mutation of the ALK gene at codon 1171 
(I1171N) (E).
